ArticleScientific reports2025
The clinical application of mitoxantrone hydrochloride tracing in endoscopic radical resection of thyroid carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Parathyroid autotransplantation into the brachioradialis protects parathyroid function during total thyroidectomy.Frontiers in endocrinology · 2026Trial
- Article
- Evaluation of mitoxantrone hydrochloride injection versus carbon nanoparticle suspension in robotic thyroidectomy for papillary thyroid carcinoma.Journal of robotic surgery · 2026Article
- Reflections on prevention and treatment of post-thyroidectomy hypoparathyroidism: current management approaches and future prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To evaluate the effectiveness of tracer mitoxantrone hydrochloride injection (MHI) in mapping central lymph nodes and its role in preserving parathyroid function during endoscopic radical resection of thyroid carcinoma. A retrospective analysis was conducted on 82 patients with primary papillary thyroid carcinoma (PTC) who were treated at the Department of General Surgery, Gansu Provincial People's Hospital, from May, 2022 to May, 2024. All patients underwent endoscopic total thyroidectomy with central lymph node dissection (CLND), with 42 receiving intraoperative tracer mitoxantrone hydrochloride injection (observation group) and 40 not receiving the injection (control group). Postoperative metrics compared between the two groups included the number of central lymph nodes dissected, the number of metastatic lymph nodes, the incidence of parathyroid gland misdissection, serum parathyroid hormone (PTH) levels, and blood calcium levels. Both groups successfully completed the surgeries. The observation group exhibited a higher number of central lymph nodes dissected and metastatic lymph nodes detected compared to the control group (P < 0.05). Additionally, the rate of parathyroid misdissection was significantly lower in the observation group (P < 0.05). From 1 week to 6 months post-operation, the observation group showed significantly higher PTH levels than the control group (P < 0.05). Similarly, blood calcium levels were significantly elevated in the observation group over the same period (P < 0.05). The incidence of temporary and permanent hypoparathyroidism was also significantly lower in the observation group (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.